Supervisor: Qiang Ding

The School of Medicine at Tsinghua University is actively advancing the construction of the Vaccine and Antibody Development Platform to ensure the smooth implementation of Tsinghua's “Innovation 2030 Initiative” and to further support the development of Tsinghua’s New Medicine. In response to the current needs of biomedical and pharmaceutical research at Tsinghua, the platform is divided into two complementary modules:

Precise Engineering of Biomacromolecules and Drug Delivery Module

Phage/Yeast Display Screening Module

These two modules work in synergy to support the development of novel vaccines and antibody drugs.

The platform plays a vital role in the prevention and treatment of infectious diseases. Its importance has become even more prominent in light of the global COVID-19 pandemic. Only by continuously strengthening the construction of such platforms can we better respond to current and future infectious disease threats, thereby safeguarding human health and life.

By 2023, the initial construction of the Vaccine and Antibody Development Platform was completed, equipped with a total of 10 instruments. The platform is focused on building phage display and yeast display systems, using phages and yeast as key vectors for monoclonal antibody and nanobody discovery, as well as for deep mutational scanning of antigen proteins. Currently, the platform has established a nanobody library in yeast cells through a yeast orthogonal replication system, enabling the screening of high-affinity antibodies targeting relevant proteins.